|
AU716731B2
(en)
*
|
1995-03-20 |
2000-03-02 |
Ko Okumura |
Monoclonal antibody reacting specifically with Fas ligand and process for producing the same
|
|
WO1996040041A2
(en)
*
|
1995-06-07 |
1996-12-19 |
Chiron Corporation |
Antibodies to fas antigen capable of inhibiting apoptosis
|
|
US6096312A
(en)
*
|
1995-06-30 |
2000-08-01 |
Mochida Pharmaceutical Co., Ltd. |
Agent for suppressing a reduction of CD4+ lymphocytes
|
|
JPH09124509A
(ja)
*
|
1995-10-27 |
1997-05-13 |
Sumitomo Electric Ind Ltd |
肝炎治療剤
|
|
DE19544333C2
(de)
*
|
1995-11-28 |
1998-12-10 |
Deutsches Krebsforsch |
Verfahren zur Beurteilung der Aktivität von Arzneistoffen
|
|
WO1997039722A2
(en)
*
|
1996-04-25 |
1997-10-30 |
T Cell Sciences, Inc. |
Method of isolating regulators of t cell activation
|
|
GB9703276D0
(en)
*
|
1997-02-17 |
1997-04-09 |
Screaton Gavin R |
Materials and methods relating to the protection of useful immune cells
|
|
CA2308017A1
(en)
*
|
1997-10-30 |
1999-05-14 |
Erik S. Falck-Pedersen |
A method of inhibiting an immune response to a recombinant vector
|
|
EP1447093A1
(en)
*
|
2003-02-14 |
2004-08-18 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
|
|
AU2004224123A1
(en)
*
|
2003-03-26 |
2004-10-07 |
Apogenix Gmbh |
Treatment of viral infections
|
|
US9309320B2
(en)
|
2006-12-28 |
2016-04-12 |
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts |
Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
|
|
ES2524553T3
(es)
|
2008-06-17 |
2014-12-10 |
Apogenix Gmbh |
Receptores multiméricos de TNF
|
|
CN102497886B
(zh)
*
|
2009-07-21 |
2016-01-20 |
玛丽皇后与斯特菲尔德学院 |
用于细胞内药物递送的Fas(Apo-1，CD95)靶向平台
|
|
SI2874659T1
(sl)
|
2012-07-18 |
2016-11-30 |
Apogenix Ag |
Inhibitorji signalizirane poti CD95 za zdravljenje MDS
|
|
EP3076179A1
(en)
|
2015-03-30 |
2016-10-05 |
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts |
Diagnosis and treatment of low grade gliomas
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
ES3055314T3
(en)
|
2017-01-06 |
2026-02-11 |
Iovance Biotherapeutics Inc |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
|
JP7780248B2
(ja)
|
2017-01-06 |
2025-12-04 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍壊死因子受容体スーパーファミリー（ｔｎｆｒｓｆ）アゴニストによる腫瘍浸潤リンパ球（ｔｉｌ）の拡大培養及びｔｉｌとｔｎｆｒｓｆアゴニストとの治療的併用
|
|
JP7349365B2
(ja)
|
2017-05-10 |
2023-09-22 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
液性腫瘍からの腫瘍浸潤リンパ球の拡大培養及びその治療的使用
|
|
JP2021503885A
(ja)
|
2017-11-22 |
2021-02-15 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
末梢血からの末梢血リンパ球（ｐｂｌ）の拡大培養
|
|
WO2019118873A2
(en)
|
2017-12-15 |
2019-06-20 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
|
MA51875A
(fr)
|
2018-02-13 |
2020-12-23 |
Iovance Biotherapeutics Inc |
Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
|
|
US20220133795A1
(en)
|
2019-03-01 |
2022-05-05 |
Iovance Biotherapeutics, Inc. |
Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof
|
|
CA3134144A1
(en)
|
2019-03-29 |
2020-10-08 |
Myst Therapeutics, Llc |
Ex vivo methods for producing a t cell therapeutic and related compositions and methods
|
|
IL293350A
(en)
|
2019-11-27 |
2022-07-01 |
Myst Therapeutics Llc |
Method of producing tumor-reactive t cell composition using modulatory agents
|
|
CN115427438A
(zh)
|
2020-02-27 |
2022-12-02 |
迈斯特治疗公司 |
肿瘤反应性t细胞的离体富集和扩增的方法及其相关组合物
|
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
WO2026044087A1
(en)
|
2024-08-21 |
2026-02-26 |
Shape Therapeutics Inc. |
Increased cellular stability for aav production
|